These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 30255262)
21. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409 [TBL] [Abstract][Full Text] [Related]
22. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Ryan EH; Pulido CM Retin Cases Brief Rep; 2015; 9(3):235-8. PubMed ID: 25790318 [TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380 [TBL] [Abstract][Full Text] [Related]
24. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report. Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772 [TBL] [Abstract][Full Text] [Related]
25. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. Yavuz S; Balsak S; Karahan M; Dursun B J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285 [TBL] [Abstract][Full Text] [Related]
26. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Bousquet E; Zhao M; Daruich A; Behar-Cohen F Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003 [TBL] [Abstract][Full Text] [Related]
27. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933 [TBL] [Abstract][Full Text] [Related]
28. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G; Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111 [TBL] [Abstract][Full Text] [Related]
29. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Sadda SR Eye (Lond); 2020 Sep; 34(9):1489-1490. PubMed ID: 32042181 [No Abstract] [Full Text] [Related]
30. Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Sacconi R; Baldin G; Carnevali A; Querques L; Rabiolo A; Marchini G; Bandello F; Querques G Eye (Lond); 2018 Apr; 32(4):734-742. PubMed ID: 29303152 [TBL] [Abstract][Full Text] [Related]
31. Eplerenone for treatment of chronic central serous chorioretinopathy. Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564 [TBL] [Abstract][Full Text] [Related]
32. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864 [TBL] [Abstract][Full Text] [Related]
33. Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy. Rübsam A; Thieme CE; Schlomberg J; Winterhalter S; Müller B; Joussen AM; Stübiger N J Ocul Pharmacol Ther; 2017 Apr; 33(3):141-148. PubMed ID: 28277988 [TBL] [Abstract][Full Text] [Related]
34. Central serous chorioretinopathy after nasal corticosteroids in the aviator. Ben Salem S; Sithom A; Ben Dhia I; Khelifi T; Askri H; Ayed A Tunis Med; 2016 Dec; 94(12):893. PubMed ID: 28994894 [No Abstract] [Full Text] [Related]
35. [Eplerenone treatment in chronic central serous chorioretinopathy]. Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892 [TBL] [Abstract][Full Text] [Related]
36. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study. Rajesh B; Agrawal H; Peguda HK; Chhablani J Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034 [TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments. Iacono P; Toto L; Costanzo E; Varano M; Parravano MC Curr Pharm Des; 2018; 24(41):4864-4873. PubMed ID: 30674250 [TBL] [Abstract][Full Text] [Related]
38. An unusual case of multifocal central serous chorioretinopathy with low serum cortisol managed using eplerenone. Aggarwal K; Agarwal A; Gupta V Indian J Ophthalmol; 2019 Jan; 67(1):167-170. PubMed ID: 30574936 [TBL] [Abstract][Full Text] [Related]
39. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Zhao M; Célérier I; Bousquet E; Jeanny JC; Jonet L; Savoldelli M; Offret O; Curan A; Farman N; Jaisser F; Behar-Cohen F J Clin Invest; 2012 Jul; 122(7):2672-9. PubMed ID: 22684104 [TBL] [Abstract][Full Text] [Related]
40. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. Gruszka A Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]